



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Attorney Docket No.: 3364.31US08

Hinz

Confirmation No.: 5651

Application No.: 10/715,912

Examiner: Lamm, M.

Filed: November 18, 2003

Group Art Unit: 1616

For: COMPREHENSIVE PHARMACOLOGIC THERAPY FOR TREATMENT OF  
OBESITY

---

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.56, and in addition to information disclosed in Applicants' Information Disclosure Statement filed April 8, 2004 and Supplemental Information Disclosure Statements filed June 6, 2005 and November 7, 2005, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The listing of a reference herein is not an admission that the reference is prior art or that the reference is material to patentability.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance.

Application No. 10/715,912

Attached is a check in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p). Please credit or debit Deposit Account No. 16-0631 as needed to ensure consideration of the disclosed information.

This application was filed after June 30, 2003; therefore copies of cited U.S. patents and U.S. published applications are not included.

Respectfully submitted,



Brian L. Stender  
Registration No. 56,836

Customer No. 24113  
Patterson, Thunte, Skaar & Christensen, P.A.  
4800 IDS Center  
80 South 8th Street  
Minneapolis, Minnesota 55402-2100  
Telephone: (612) 252-1548

*Please grant any extension of time necessary for entry; charge any fee due to Deposit Account No. 16-0631.*

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

2/8/06  
Date of Deposit

  
Brian L. Stender

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i> Application Number      10/715,912 Filing Date                November 18, 2003 First Named Inventor      Hinz Art Unit                      1616 Examiner Name              Lamm, M. Attorney Docket Number    3364.31US08	
Sheet	1	of			
<b>U.S. PATENT DOCUMENTS</b>					
EXAMINER INITIAL*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number-Kind Code <sup>2</sup> (if known)			
		US-4,237,118	12-02-1980	Howard	
		US-5,019,594	05-28-1991	Wurtman et al.	
		US-5,084,007	01-28-1992	Malin et al.	
		US-5,977,099	11-02-1999	Nickolson	
		US-6,048,728	04-11-2000	Inlow et al.	
		US-6,335,323	01-01-2002	Worsley	
		US-6,384,088	05-07-2002	Hinz	
		US-6,548,551	04-15-2003	Hinz	
		US-6,759,437	07-06-2004	Hinz	
<b>FOREIGN PATENT DOCUMENTS</b>					
EXAMINER INITIAL*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
<b>NON PATENT LITERATURE DOCUMENTS</b>					
EXAMINER INITIAL*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
		ABELL, "Placebo controlled double-blind trial fluvoxamien maleate in the obese", J. Psychosom Res, 30(2): 143-146 (1986).			
		BOUCHARD, "Citalopram and viloxazine in the treatment of depression by means of slow drop infusion, A double blind comparative trial", J Affect Disord, 46(1): 51-8 (1997).			
		MAREK ET AL., "A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action", Psychopharmacology 109:2-11 (1992).			
		MOON, "The Effects of Psychomotor Performance of Fluvoxamine Versus Mianserin in Depressed Patients in General Practice", BJCP, 45(4): 259-262.			
EXAMINER SIGNATURE		DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p><sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p>					